GSK

GLAXF

Drug Manufacturers - General · Healthcare

Price

$26.50

+1.19 (+4.69%)

Market Cap

$106.15B

Exchange

Other OTC

Winston Score

Winston is happy

A high-quality business with solid fundamentals.

Data as of Jul 28, 2026 · filings through Mar 31, 2026

Share count rising — dilution

+27.0% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 3.24B (2021) → 4.12B (2025)

GSK plc is a British pharmaceutical company that makes medicines and vaccines sold to patients, hospitals, and governments around the world. Its key products include HIV treatments (through its ViiV Healthcare unit), respiratory drugs like Nucala, and vaccines for diseases like shingles (Shingrix) and meningitis. GSK is one of the largest drugmakers in the world and is a leader in the HIV treatment market.

GSK earns money by selling prescription medicines and vaccines to healthcare systems, pharmacies, and clinics globally. It operates across more than 100 countries, with major revenue coming from the US, Europe, and international markets. Its competitive edge comes from a deep pipeline of specialty medicines and a strong vaccines portfolio, which are harder to copy than standard drugs. The biggest risk GSK faces is patent expiration on key products, which allows cheaper generic competitors to enter the market and cut into revenue.

Winston Score History

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

75.4%

Premium pricing power — 75.4% gross margin

Operating Margin

30.1%

Excellent — 30.1% operating margin

ROCE

6.2%

Weak — 6.2% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-2.5%

Shrinking sales (-2.5% YoY)

EPS YoY

+71.4%

Earnings growing fast (71.4% YoY)

Earnings growing 25%+ a year. The compounder zone.

EPS Consistency

8/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

143%

Turns 143% of profit into real cash

FCF Margin

18.4%

Converts sales into free cash efficiently (18.4%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

1.07

Elevated debt (1.07)

Interest Cover

10.89x

Comfortably covers interest (10.9x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

19.9x

Fair value — P/E 19.9

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

P/E vs Forward

+7.0

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (19.9 → 12.9)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend Yield

3.42%

Moderate income — 3.42% yield

Standard yield zone for stable dividend payers. A meaningful piece of total return.

Dividend Growth

+12.5%

Dividend growing fast (12.5% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial